Mostrar el registro sencillo del ítem

dc.contributor.author
Rosselli, Maria Soledad  
dc.contributor.author
Burgueño, Adriana Laura  
dc.contributor.author
Carabelli, Julieta  
dc.contributor.author
Schuman, Mariano Luis  
dc.contributor.author
Pirola, Carlos José  
dc.contributor.author
Sookoian, Silvia Cristina  
dc.date.available
2020-05-20T19:58:52Z  
dc.date.issued
2009-09  
dc.identifier.citation
Rosselli, Maria Soledad; Burgueño, Adriana Laura; Carabelli, Julieta; Schuman, Mariano Luis; Pirola, Carlos José; et al.; Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model; Elsevier Ireland; Atherosclerosis; 206; 1; 9-2009; 119-126  
dc.identifier.issn
0021-9150  
dc.identifier.uri
http://hdl.handle.net/11336/105628  
dc.description.abstract
OBJECTIVE: To evaluate the effect of losartan-an angiotensin II type 1 receptor (AT1R) antagonist- and telmisartan-an AT1R blocker with insulin-sensitizing properties-, on the hepatic expression of plasminogen activator inhibitor-1 (PAI-1) in a rat model of nonalcoholic fatty liver disease (NAFLD). METHODS: Rats were given a high-fat diet (HFD) for 8 weeks and after this period were randomly divided into 3 groups. For 12 weeks along with the same access to HFD, one group (9 rats) received losartan and another group received telmisartan (10 rats), both at 10mg/kg intraperitoneally (ip) every 24h. The third group (8 rats) received saline ip along with the HFD. Finally, a control group (6 rats) was fed with standard chow diet for 20 weeks. RESULTS: Fatty liver was reverted by both losartan and telmisartan. Both drugs had beneficial effects on insulin resistance, reaching statistical significance in telmisartan group. Expression of hepatic mRNA of PAI-1 showed a 42% decrease in losartan-treated rats in comparison with both HFD group and telmisartan-treated rats. To further evaluate this differential effect on PAI-1 expression, we explored the effect of the drugs on liver expression of TNFalpha, PEPCK-C and PPARalpha, and no significant differences were observed. CONCLUSION: These results indicate that AT1R blockers could be eligible drugs for reducing hepatic lipid accumulation in patients with NAFLD. However, only 12 weeks of losartan treatment strongly reduced hepatic PAI-1 gene expression. These differences could provide even more effective options for preventing fatty liver disease and its cardiovascular complications.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Elsevier Ireland  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
NONALCOHOLIC FATTY LIVER DISEASE  
dc.subject
PLASMINOGEN ACTIVATOR INHIBITOR-1  
dc.subject
ANGIOTENSIN II RECEPTOR BLOCKER  
dc.subject
ANGIOTENSIN II TYPE 1 RECEPTOR  
dc.subject
LOSARTAN  
dc.subject
TELMISARTAN  
dc.subject.classification
Fisiología  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2020-05-05T16:06:02Z  
dc.journal.volume
206  
dc.journal.number
1  
dc.journal.pagination
119-126  
dc.journal.pais
Irlanda  
dc.description.fil
Fil: Rosselli, Maria Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina  
dc.description.fil
Fil: Burgueño, Adriana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina  
dc.description.fil
Fil: Carabelli, Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina  
dc.description.fil
Fil: Schuman, Mariano Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina  
dc.description.fil
Fil: Pirola, Carlos José. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina  
dc.description.fil
Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina  
dc.journal.title
Atherosclerosis  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.atherosclerosis-journal.com/article/S0021-9150(09)00073-2/abstract  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/abs/pii/S0021915009000732  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1016/j.atherosclerosis.2009.01.026